Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Posters, Tuesday and Wednesday<br />
Index of Poster Presenters cont’d<br />
29P10<br />
The Year <strong>in</strong> Review: Describ<strong>in</strong>g Prophylaxis and Adherence<br />
<strong>in</strong> Children with Severe Hemophilia A Us<strong>in</strong>g Patient Infusion<br />
Diaries<br />
Bos C, Chan A, Webert K, Almonte T, Decker K, Goldsmith R<br />
McMaster Hemophilia Cl<strong>in</strong>ic, Hamilton ON, Canada<br />
29P11<br />
Prophylaxis with rFVIIa Three Times a Week for Patients with<br />
Severe Hemophilia and Inhibitors: A S<strong>in</strong>gle Centre Experience<br />
Cermelj M, Gerardo P, Pollola J<br />
Department of Haemophilia, Instituto William Osler, CABA,<br />
Buenos Aires, Argent<strong>in</strong>a<br />
29P12<br />
Turn<strong>in</strong>g Severe <strong>in</strong>to Moderate Hemophilia by Prophylaxis;<br />
Are We Reach<strong>in</strong>g Our Goal?<br />
den Uijl IEM1,2 , Grobbee DE2 , Fischer K1,2 1Van Creveldkl<strong>in</strong>iek, Dept Haematology, UMC Utrecht, the<br />
Netherlands, 2Julius Center for Health Sciences and Primary<br />
Care, UMC Utrecht, the Netherlands<br />
29P13<br />
International Study Demonstrates the Benefits of Prophylaxis<br />
Coll<strong>in</strong>s P1 , Giangrande P2 , Blanchette V3 , Epste<strong>in</strong> J4 , Xiong<br />
Y4 , Li-McLeod J4 1University Hospital of Wales, Cardiff, United K<strong>in</strong>gdom,<br />
2 3 Churchill Hospital, Oxford, United K<strong>in</strong>gdom, Hospital for<br />
Sick Children, Toronto, ON, Canada, 4Baxter BioScience,<br />
Westlake Village, CA, U.S.A.<br />
29P14<br />
Prophylaxis <strong>in</strong> Hemophilia <strong>in</strong> Tunisia<br />
Gouider E and Meddeb KB<br />
Hemophilia Treatment Centre Aziza Othmana Hospital<br />
Tunisia, Tunis, Tunisia<br />
29P15<br />
Clott<strong>in</strong>g Factor Concentrates Given to Prevent Bleed<strong>in</strong>g and<br />
Bleed<strong>in</strong>g-Related Complications <strong>in</strong> People with Hemophilia<br />
A or B<br />
Iorio A1 , Marches<strong>in</strong>i E1 , Marcucci M1 , Kent S2 1 2 Unversity of Perugia, Perugia, Italy, University of Alberta,<br />
Calgary, AB, Canada<br />
29P16<br />
Prophylaxis <strong>in</strong> Hemophilic Children <strong>in</strong> Poland<br />
Klukowska A, Laguna P, Matysiak M<br />
Dept. Pedriatrics, Hematology and Oncology WUM, Warsaw,<br />
Poland<br />
82<br />
29P17<br />
Prophylaxis with Novoseven® <strong>in</strong> Factor VII Deficiency:<br />
Prelim<strong>in</strong>ary Results from STER (Seven Treatment Evaluation<br />
Registry)<br />
Auerswald G1, Michaels L, Altisent C., Di M<strong>in</strong>no G., Dolce<br />
A., Napolitano M., Mariani G., on behalf of the STER Study<br />
Group<br />
29P18<br />
Comparison of Prophylaxis, On-Demand, or Comb<strong>in</strong>ed<br />
Treatment <strong>in</strong> 20-35 Year Old Males with Severe Hemophilia<br />
<strong>in</strong> 4 European Countries<br />
O’Mahony B, Noone D<br />
Irish Haemophilia Society, Dubl<strong>in</strong>, Ireland<br />
29P19<br />
An Economic Model to Evaluate the Cost-Effectiveness of<br />
Prophylaxis Regimens on Hemophilia Patients with Inhibitors<br />
Knight C1 , Plun-Favreau J2 , Johal S1 1 2 RTI Health Solutions, Zurich, Switzerland, Novo Nordisk,<br />
Zurich, Switzerland<br />
29P20<br />
Long-Term FEIBA Prophylaxis <strong>in</strong> Pediatric Hemophilia A<br />
Patients with High-Titer Inhibitors<br />
Saxena, K1 , Hawk S2 , S<strong>in</strong>gh P2 , Stevens B2 , and Sexauer C2 1 2 Children’s Hospital, Boston, MA, U.S.A. and University of<br />
Oklahoma Children’s Hospital, Oklahoma City, Oklahoma,<br />
U.S.A.<br />
29P21<br />
LA-N8, A New Long-Act<strong>in</strong>g Recomb<strong>in</strong>ant FVIII with<br />
Prolonged Hemostatic Effect <strong>in</strong> a FeCl3 Induced Injury Model<br />
<strong>in</strong> F8-KO Mice<br />
Møller F, Tranholm M, Kjalke M, Thim L, Olsen E,<br />
Jespersgaard C<br />
Novo Nordisk A/S, Maaloev, Denmark<br />
29P22<br />
LA-N8, A New Long-Act<strong>in</strong>g rFVIII with Prolonged Hemostatic<br />
Effect <strong>in</strong> a Mur<strong>in</strong>e Jo<strong>in</strong>t Bleed<strong>in</strong>g Model <strong>in</strong> FVIII-Deficient<br />
Mice<br />
Øvlisen K, Tranholm M, Olsen E, Kjalke M, Thim L, Stennicke H<br />
Novo Nordisk A/S, Maaloev, Denmark<br />
PSYCHOSOCIAL ISSUES<br />
30P17<br />
Systemic Family Therapy: An Effective Tool to Manage<br />
Hemophiliac’s Family Dynamic<br />
Vall<strong>in</strong> Antunes S1 , dos Reis Tomaz M1 , de Morais Horta A2 1Universidade Federal de São Paulo -Depto Oncologia Cl<strong>in</strong>ica<br />
e Experimental, 2Universidade Federal de São Paulo, Depto<br />
de Enfermagem, Brazil